Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA® in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus

Overview

The purpose of this research study is to measure how much of the study drug (Afrezza) gets into your blood
after a single dose and measure how well it works to control your blood sugar level. We also want to make sure
this study drug is safe for children and adolescents between 4 and 17 years old.

Description

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions: type 1 diabetes mellitus
  • Age: Between 4 Years - 12 Years
  • Gender: Male or Female

Inclusion Criteria

Diagnosed with Type 1 diabetes for at least 1 year

Currently on multiple daily injections

No history of asthma

Updated on 20 Nov 2022 . Study ID: TX10301

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center